Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2
作者:Rena Lapidus、Brandon Carter-Cooper、Mariola Sadowska、Eun Choi、Omasiri Wonodi、Nidal Muvarak、Karthika Natarajan、Lakshmi Pidugu、Anil Jaiswal、Eric Toth、Feyruz Rassool、Arash Etemadi、Edward Sausville、Maria Baer、Ashkan Emadi
DOI:10.3390/ph9010004
日期:——
Selective targeting of the oxidative state, which is a tightly balanced fundamental cellular property, is an attractive strategy for developing novel anti-leukemic chemotherapeutics with potential applications in the treatment of acute myeloid leukemia (AML), a molecularly heterogeneous disease. Dimeric naphthoquinones (BiQs) with the ability to undergo redox cycling and to generate reactive oxygen species (ROS) in cancer cells are a novel class of compounds with unique characteristics that make them excellent candidates to be tested against AML cells. We evaluated the effect of two BiQ analogues and one monomeric naphthoquinone in AML cell lines and primary cells from patients. All compounds possess one halogen and one hydroxyl group on the quinone cores. Dimeric, but not monomeric, naphthoquinones demonstrated significant anti-AML activity in the cell lines and primary cells from patients with favorable therapeutic index compared to normal hematopoietic cells. BiQ-1 effectively inhibited clonogenicity and induced apoptosis as measured by Western blotting and Annexin V staining and mitochondrial membrane depolarization by flow cytometry. BiQ-1 significantly enhances intracellular ROS levels in AML cells and upregulates expression of key anti-oxidant protein, Nrf2. Notably, systemic exposure to BiQ-1 was well tolerated in mice. In conclusion, we propose that BiQ-induced therapeutic augmentation of ROS in AML cells with dysregulation of antioxidants kill leukemic cells while normal cells remain relatively intact. Further studies are warranted to better understand this class of potential chemotherapeutics.
氧化态是一种紧密平衡的基本细胞特性,选择性靶向氧化态是开发新型抗白血病化疗药物的一种有吸引力的策略,在治疗急性髓性白血病(AML)这种分子异质性疾病方面具有潜在应用。二聚萘醌 (BiQ) 能够进行氧化还原循环并在癌细胞中产生活性氧 (ROS),是一类具有独特特性的新型化合物,使其成为针对 AML 细胞进行测试的绝佳候选物。我们评估了两种 BiQ 类似物和一种单体萘醌对 AML 细胞系和患者原代细胞的作用。所有化合物在醌核上都具有 1 个卤素和 1 个羟基。与正常造血细胞相比,二聚体而非单体萘醌在治疗指数良好的患者的细胞系和原代细胞中表现出显着的抗 AML 活性。通过蛋白质印迹和膜联蛋白 V 染色以及通过流式细胞术测定线粒体膜去极化来测量,BiQ-1 有效抑制克隆形成并诱导细胞凋亡。 BiQ-1 显着增强 AML 细胞中的细胞内 ROS 水平,并上调关键抗氧化蛋白 Nrf2 的表达。值得注意的是,小鼠对 BiQ-1 的全身暴露具有良好的耐受性。总之,我们提出,BiQ 诱导的 AML 细胞中 ROS 的治疗性增强以及抗氧化剂失调可杀死白血病细胞,而正常细胞则保持相对完整。需要进一步研究以更好地了解此类潜在化疗药物。